Učitavanje...
Effect of Concomitant Hydroxyurea Therapy with Rutin and Gallic Acid: Integration of Pharmacokinetic and Pharmacodynamic Approaches
[Image: see text] Hydroxyurea (HU) is the first-ever approved drug by USFDA for sickle cell anemia (SCA). However, its treatment is associated with severe side effects like myelosuppression. Current studies are focused on the supplementation therapy for symptomatic management of SCA. In the present...
Spremljeno u:
| Izdano u: | ACS Omega |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Chemical Society
2021
|
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8190911/ https://ncbi.nlm.nih.gov/pubmed/34124477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.1c01518 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|